01393nas a2200217   4500000000100000008004100001260000900042653001200051653002000063653003300083653001100116653002300127653001200150653000900162245004200171856008300213300001100296490000700307520084700314022001401161       1976                            d  c197610aAnimals10aDrug Evaluation10aDrug Evaluation, Preclinical10aHumans10aLeprostatic Agents10aleprosy10aMice00aExperimental chemotherapy in leprosy.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2366517/pdf/bullwho00460-0118.pdf  a425-330 v533 a<p>The Memorandum reviews the considerable progress that has been made in research on the chemotherapy of leprosy during the last 10-15 years, as a result of which it is now possible to study the same topics in leprosy as are studied in other bacterial diseases. Thus drugs have been screened in mice for their activity against Mycobacterium leprae. Those that have been found to have the greatest activity against M. leprae at acceptable dosages-dapsone, rifampicin, and clofazimine-have been characterized in terms of the minimal effective dosage and rate of bacterial kill. Similarly, their pharmacokinetics in man and in certain animals have been defined. The theoretical basis for drug trials in leprosy patients is discussed in terms of the number of viable and the number of dead M. leprae that remain at various stages of therapy.</p>  a0042-9686